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Abstract: Chronic heart failure (HF) is a cardiovascular disease of cardinal importance because 
of several factors: a) an increasing occurrence due to the aging of the population, primary 
and secondary prevention of cardiovascular events, and modern advances in therapy, b) a bad 
  prognosis: around 65% of patients are dead within 5 years of diagnosis, c) a high economic cost: 
HF accounts for 1% to 2% of total health care expenditure. This review focuses on the main 
causes, consequences in terms of morbidity, mortality and costs and treatment of HF.
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Definition, classification, and occurrence  
of heart failure
Heart failure (HF) is a complex clinical syndrome caused by structural or functional 
cardiac disorders that impair the ability of one or both ventricles to fill with or eject 
blood.1 For the diagnosis of HF, symptoms (typically shortness of breath at rest or 
during exertion and/or fatigue), signs of fluid retention (such as pulmonary congestion 
and/or ankle swelling), and objective evidence of a decrease in myocardial performance 
at rest (normally demonstrated in an echocardiography study) are required.2   According 
to the time from ventricular dysfunction to clinical manifestations, left ventricular 
ejection fraction (LVEF), and the main site of congestion, HF can be divided into dif-
ferent groups (Figure 1). Generally, it is a chronic condition with bouts of worsening 
symptoms that may require medical attention (decompensations). However, it may 
present acutely within just 24 hours in the form of pulmonary edema or even cardiogenic 
shock. Conventionally, HF was seen to result from the failure of the heart to pump 
enough blood into the circulation due to ventricular systolic dysfunction defined as 
LVEF , 40% to 50% (HF with depressed ejection fraction [HFDEF]).2 Nevertheless, 
patients with nondecreased LVEF can develop HF when higher filling pressures are 
needed to achieve a normal end-diastolic ventricular volume (HF with preserved ejec-
tion fraction [HFPEF]). The occurrence of this condition is more common in women, 
in the elderly, and in persons with longstanding high blood pressure (HBP) and is 
associated with a similar prognosis to HFDEF.3,4 Right and left HF refer to syndromes 
presenting predominantly with systemic or pulmonary congestion leading to jugular 
venous ingurgitation and ankle swelling or pulmonary edema, respectively.
Generally speaking, the prevalence of HF can be estimated at 1% to 2% in Western 
countries and the incidence approaches 5 to 10 per 1000 persons per year. Data on the 
occurrence of HF in the developing world are largely absent. This high prevalence is Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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increasing because of the aging population, the success in 
primary and secondary prevention of coronary events, and 
the development of modern treatments. The mean age of 
patients with HF in industrialized societies is approximately 
75 years.5
This review will focus on the main causes, consequences 
(in terms of morbidity, mortality, and economic costs), and 
treatment of chronic HF.
Causes of HF
Although many conditions may lead to HF, the predominant 
etiologies are myocardial ischemia and HBP (Table 1). The 
discrepancies in the frequency of causes reported in the 
  medical literature can be explained by differences in the study 
population (from highly selected participants in clinical 
trials to relatively unselected subjects in population-based 
studies, respectively), definitions (eg, consensus on a cut-off 
value for LVEF to define HFPEF has not been reached), and 
time period (eg, the Framingham heart study originated in 
1948). Furthermore, it has become clear that by using only 
noninvasive techniques, precise etiology cannot always be 
determined. For instance, in the Bromley HF study after 
nuclear testing and cardiac catheterization the percentage of 
HF with unknown cause declined from 42% to 10%, while the 
percentage of patients with ischemic heart disease increased 
from 29% to 52%.6
Myocardial ischemia
Coronary artery disease (CAD) may be the initiating cause 
in ≈70% of cases of HF.7 Even in HF individuals clinically 
classified as nonischemic, evidence of ischemia has been 
found. Up to 25% may have significant atherosclerosis 
plaques in the coronary trees at autopsy,8 which points out 
the limited diagnostic accuracy of image techniques such 
as angiography. Besides, it has been reported that these 
patients may suffer ischemic events on the follow-up, a find-
ing that suggests that CAD may not be just a ‘bystander’.9 
Moreover, the high prevalence of a reduced flow reserve 
demonstrated in subjects with HF and nonsignificant steno-
sis in the main coronary arteries incriminates microvascular 
impairment as a potential contributor to their myocardial 
dysfunction.10,11
Mechanisms of HF in CAD (Figure 2)
1.  Acute myocardial infarction (MI) frequently causes 
the death of the myocytes of one or more ventricular 
segments that become scarred, resulting in inadequate 
relaxation in diastole and impaired contraction in 
systole. Further decrease in ventricular performance 
may occur if an aneurysm is developed. MI can also 
predispose to HF by the dyssynchronous movement of 
the infarct area that can lessen the efficiency of pump 
function.
2.  Whereas the initial myocardial scarring results in local 
dysfunction, remodeling in remote areas of the left 
ventricle (LV) may take place resulting in a distortion 
of the ventricular structure and geometry, which can 
contribute to an additional decrement of ventricular 
function.12 Besides, ventricular enlargement may 
promote dysfunction of the mitral apparatus with the 
consequent mitral regurgitation (MR), which can pre-
dispose to HF.
Time from ventricular dysfunction
to clinical manifestations
Acute HF Chronic HF
Ejection fraction
Main site of congestion
≥ 40%–50%: HFPEF < 40%–50%: HFDEF
Systemic
circulation: Right HF
Pulmonary
circulation: Left HF
Figure 1 Types of heart failure.
Abbreviations: HF, heart failure; HFDeF, heart failure with depressed ejection 
fraction; HFPeF, heart failure with preserved ejection faction.
Table 1 Main causes of heart failure
• Myocardial ischemia
• HBP
• Cardiomyopathies
• Valvular heart disease
• PHT
• Congenital heart disease
Abbreviations: HBP, high blood pressure; PHT, pulmonary hypertension. See text 
for details.
Acute
ischemia
Chronic
ischemia CAD
HF
Scar Remodeling
Dyssynchrony
Aneurysm
Tachyarrythmias Hibernation
Figure 2 From coronary artery disease to heart failure.
Abbreviations: CAD, coronary artery disease; HF, heart failure.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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3.  Several tachyarrhythmias such as nonsustained ventricu-
lar tachycardia (NSVT) or atrial fibrillation/atrial flutter 
(AF), common in patients with CAD, can deteriorate 
cardiac function.
	•     Loss of atrial contraction in AF decreases ventricular 
filling and stroke volume.
	•     Systolic volume is diminished during NSVT due to 
atrioventricular dissociation and the consequent drop 
of preload.
	•     Diastolic time shortening, found in both arrhythmias, 
also contributes to the lessening of filling and cardiac 
output.
	•     When AF and NSVT are persistent they may 
lead to tachycardia-induced cardiomyopathy 
(tachycardiomyopathy).13
4.  Maintained reduction in blood supply due to chronic 
severe coronary stenosis may result in low myocardial 
performance (hibernation).14
HBP
HBP boosts HF risk by two- to three-fold.15,16 Although the 
relative risk of developing HF in HBP is modest, its high 
  prevalence renders it a cause in approximately one-third of 
cases.17 Besides, HBP is an independent risk factor for CAD.
effects of HBP in the heart
In hypertensive patients, the myocardium has to pump blood 
against a higher afterload posed by the elevated resistance of the 
peripheral vasculature.This condition leads to a compensatory 
increase in myocardial mass in order to maintain normal 
cardiac output. Left ventricular hypertrophy (LVH) in HBP is 
characterized not only by enlargement of the cardiac myocytes 
but also by an increase of interstitial and perivascular 
fibrosis.18 The progression from a structurally normal heart 
to LVH is not solely a consequence of enhanced afterload; 
many mechanisms are known to be involved, particularly the 
renin–angiotensin–aldosterone system (RAAS).19
Mechanisms of HF in HBP (Figure 3)
1.  Hypertrophic ventricles are characterized by a higher 
myocardial stiffness and a decreased ability to relax and 
fill.20–23
2.  HBP is associated with myocardial ischemia even 
in the absence of CAD. Three main mechanisms are 
implicated:24
	•     In HBP, the growth of the coronary bed does not 
keep pace with the increase in cardiac mass, proving 
a ‘set up’ for chronic ischemia.
	•     Coronary arteries travel across ventricular walls from 
the epicardium to the endocardium, perfusing the 
myocardium mainly during diastole due to a positive 
ratio between the intravessel and parietal pressures. 
Such a ratio is reduced in HBP as a consequence of 
the high ventricular chamber pressure transmitted to 
the walls, which promotes ischemia. This effect is 
more pronounced at the subendocardial level.
	•     Coronary flow reserve is impaired due to structural 
and functional changes in the arterioles (medial wall 
thickening and perivascular fibrosis boost vessel resis-
tance, endothelial dysfunction impairs vasodilatation 
capacity).
These conditions may lead to HFPEF. Persistent work 
overload, hypoxia, and neurohumoral stimulation in long-
standing uncontrolled HBP can promote myocyte apoptosis 
and eventually systolic dysfunction.25
Cardiomyopathies
According to the new classification recently published by the 
Working Group on Myocardial and Pericardial Diseases of 
the European Society of Cardiology, a cardiomyopathy is a 
↑ RAAS ↑ VR
LVH
HBP
↑ Myocardial
stiffness
HFPEF
HFDEF
Maintained
uncontrolled HBP
Myocytes
apoptosis
Ischemia
Figure 3 From high blood pressure to heart failure.
Abbreviations: HBP, high blood pressure; HFDeF, heart failure with depressed 
ejection fraction; HFPeF, heart failure with preserved ejection fraction; LVH, left 
ventricular hypertrophy; RAAS, renin–angiotensin–aldosterone system; VR, vascular 
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myocardial disorder in which the heart muscle is   structurally 
and functionally abnormal in the absence of CAD, HBP, 
valvular, or congenital heart disease severe enough to cause 
the observed myocardial abnormality. Cardiomyopathies are 
grouped into five specific phenotypes: dilated cardiomyopathy 
(DCM), hypertrophic cardiomyopathy (HCM), restrictive 
cardiomyopathy (RCM), arrhythmogenic right ventricular 
cardiomyopathy (ARVC), and other unclassified cardiomyo-
pathies (isolated noncompaction of the left ventricle [INLV] 
and Takotsubo syndrome are included in this category). Each 
phenotype is subclassified into familial and nonfamilial forms 
taking into account the presence or absence in more than 
one member of the family, of either the same disorder or a 
phenotype that is (or could be) caused by the same genetic 
mutation. Nonfamilial cardiomyopathies are divided into 
idiopathic (when no identifiable cause is found) or acquired 
forms (in which ventricular dysfunction is a complication of 
the disorder rather than an intrinsic feature of the disease).26
DCM
This entity is much more common by far than the other 
major types of cardiomyopathies. DCM is a heterogeneous 
disease characterized by left ventricular and sometimes 
atrial   dilation (right ventricular enlargement and dysfunc-
tion may be present but is not necessary for the diagnosis), 
with normal or reduced wall thickness eventually leading to 
varying degrees of impaired systolic function. The clinical 
picture at the time of diagnosis can vary widely from patient 
to patient; some have no symptoms, whereas others develop a 
progressive refractory HF. When the etiology is investigated 
with specialized techniques, at least 25% of patients have 
evidence of familial disease with predominantly autosomal 
dominant inheritance.27,28 Frequent nonfamilial acquired 
causes of DCM include cardiotoxic drugs such as anthracy-
clines, alcohol, or cocaine, late stage of cardiac infectious 
and inflammatory diseases (myocarditis), and persistent 
tachyarrhythmias (tachycardiomyopathy) (Table 2).
HCM
The new classification has redefined HCM as the presence of 
an increased ventricular wall thickness or mass in the absence 
of loading conditions (HBP, valve disease) sufficient to cause 
the observed abnormality.26 Following this new definition, 
those diseases in which ventricular mass is increased due to 
interstitial infiltration or intracellular accumulation of meta-
bolic substrates are included in this category (Table 3).
LVH in the absence of HBP and valve disease occurs 
in approximately 1 in 500 of the general population. 
Many   individuals have a familial disease with an autosomal 
dominant pattern of inheritance. Mutations identified in these 
patients affect genes that encode different proteins of the cardiac 
  sarcomere. HCM caused by such mutations predominantly 
has an asymmetrical pattern of LVH, the interventricular 
septum segments being the most frequently affected, and 
myocyte disarray.29 LV volume is usually small and LVEF 
preserved. Symptoms are related to an impaired ventricular 
filling (HFPEF), and in some cases, to left outflow track 
dynamic obstruction. Progression to LV dilatation and systolic 
dysfunction is rare (from 2.5% up to 15% in some series).30
Although all types of LVH may be present in sarcomeric 
protein disease, concentric forms are more common in 
metabolic disorders (eg, Anderson–Fabry disease). Other 
differential features that may help in the diagnosis of these 
entities are the inheritance pattern (X-linked, autosomal 
recessive) and the presence of signs and symptoms derived 
from multisystemic affectation.26
Table 2 Causes of dilated cardiomyopathy
Familial
Unknown gene mutations
Known gene mutations
	•  Sarcomeric proteins
	•    Others (include z-ban, cytoskeleton, nuclear membrane, intercalated 
disc, mitochondrial gene mutations)
Nonfamilial
Nutritional deficiencies
	•  Thiamine
	•  Carnitine
	•  Selenium
	•  Hypophosphatemia
	•  Hypocalcemia
endocrine dysfunction
	•  Diabetes mellitus
	•  Hypo/hyperthyroidism
	•  Cushing syndrome
	•  Adrenal insufficiency
	•  excessive growth hormone
	•  Phaeochromocytoma
Cardiotoxic drugs
	•  Cytotoxic agents (eg, anthracyclines)
	•  Alcohol
	•  Cocaine
Myocarditis
	•  infective
	•  immune
Pregnancy
	•  Peripartum cardiomyopathy
Tachycardiomyopathy
	•    Atrial tachyarrhythmias  
(atrial fibrillation-atrial flutter, atrial tachycardia)
	•  Junctional tachycardiaVascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Athletic training is associated with physiological LVH that 
can be misinterpreted as a pathological phenotype, but the degree 
of wall thickness is much less pronounced (,13 mm in septal 
segments in most cases) and diastolic function is normal.31
RCM
This cardiomyopathy is characterized by a severe diastolic 
  dysfunction (restrictive physiology) in the presence of nor-
mal or reduced diastolic volumes (of one or both ventricles), 
  normal or reduced systolic volumes, and normal ventricular 
wall   thickness. Although historically, systolic function has been 
said to be preserved in RCM, contractility is not completely 
normal in this entity.26 Although the exact prevalence of RCM 
is unknown it is probably the least prevalent type of cardiomyo-
pathy. RCM may be idiopathic, familial, or result from various 
systemic   disorders (Table 4). As can be seen from comparing 
Tables 3 and 4, several genetic mutations and infiltrative diseases 
may present with a restrictive or hypertrophic phenotype.
ARVC
Ventricular arrhythmias and sudden cardiac death (SCD) 
are the main manifestations of this rare cardiomyopathy 
Table 3 Causes of hypertrophic cardiomyopathy
Familial
	•  Unknown gene mutations
	•  Sarcomeric protein mutations
	•  Glycogen storage disease
  ○  Pompe
  ○  PRKAG2
  ○  Forbes’
  ○  Danon
	•  Lysosomal storage diseases
  ○  Anderson–Fabry
  ○  Hurler’s
	•  Syndromic HCM
  ○  Noonan’s syndrome
  ○  LeOPARD syndrome
  ○  Friedreich’s ataxia
  ○  Beckwith–wiedermann syndrome
  ○  Swyer’s syndrome
	•  Familial amyloid
	•    Others (disorders of fatty acid metabolism, carnitine deficiency, 
phosphorylase B kinase deficiency, mitochondrial cytopathies, 
phospholamban promoter)
Nonfamilial
	•  Obesity
	•  infants of diabetic mothers
	•  Athletic training
	•  Amyloid
  ○  AL
  ○  Prealbumin
Abbreviations: AL, amyloidosis; HCM, hypertrophic cardiomyopathy.
Table 4 Causes of restrictive cardiomyopathy
Familial
	•  Unknown gene
	•  Sarcomeric protein mutations
	•  Familial amyloidosis
		○ Transthyretin (RCM + neuropathy)
		○ Apolipoprotein (RCM + nephropathy)
	•  Anderson–Fabry disease
	•  Glycogen storage diseases
	•  Hemochromatosis
	•  Ohers (desminopathy, pseuxanthoma elasticum)
Nonfamilial
	•  Amyloid
		○ AL
		○ prealbumin
	•  Scleroderma
	•  Endomyocardial fibrosis
		○ Hypereosinophilic syndrome
		○ idiopathic
		○ Chromosomal cause
		○   Drugs (serotonin, methysergide, ergotamine, mercurial agents, 
busulfan)
	•  Carcinoid heart disease
	•  Metastatic cancers
	•  Radiation
	•  Drugs (anthracyclines)
Abbreviations: AL, amyloidosis; RCM, restrictive cardiomyopathy.
(1/1000–5000). Although uncommon, right ventricular or 
biventricular HF mimicking a DCM may be present.32
iNLV
INLV is an infrequent unclassified cardiomyopathy (0.014% 
of consecutive echocardiograms) assumed to occur due to an 
arrest in the compaction process of the LV during the normal 
development of the heart. This entity is morphologically charac-
terized by the appearance of prominent trabeculations and deep 
intertrabecular recesses mainly in the apex and in the inferior 
and lateral mid segments, with an endsystolic ratio between 
the noncompacted subendocardial layer and the compacted 
  subepicardial layer .2. The clinical presentation of INLV 
includes a high prevalence of HF, thromboembolic events 
and arrhythmias including ventricular tachycardia and AF.33 
INLV is commonly familial, with at least 25% of asymptomatic 
relatives having a range of echocardiographic abnormalities.34 
Causative mutations in several genes have been identified.26
Valvulopathies
A severe increase in ventricular afterload may lead to HF in 
severe aortic and pulmonary stenosis. In valve regurgitation, 
a persistent volume overload may cause ventricular enlarge-
ment and functional impairment.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Other causes of HF
The elevated resistance of the pulmonary vasculature in 
pulmonary hypertension may promote right HF. A special 
case of this condition is observed in patients with chronic 
obstructive pulmonary disease (cor pulmonale).
Congenital heart diseases such as interventricular and 
interatrial communication or persistent arterial ductus can 
lead to HF due to maintained volume overload.
Consequences of HF
Reduction of functional capacity
Functional capacity in HF patients is limited by shortness 
of breath and fatigue on exertion. A basic   pathophysiology 
of these symptoms can be summarized in two points 
(Figure 4):
1.  When diastolic dysfunction is developed the failing 
heart requires a higher LV filling pressure to maintain 
output, particularly during exertion. The filling pressure 
of the LV can become high enough to cause stiff lungs 
or even transudation of fluid into the alveoli leading to 
breathlessness.
2.  If systolic function is impaired, the failing heart may 
be unable to increase the stroke volume adequately in 
response to exercise. In turn, this leads to the inability to 
perfuse the exercising muscle effectively. The affected 
skeletal muscle signals the brain, and this sensation is 
interpreted as fatigue.
Although this view regards HF as a hemodynamic disorder, 
many studies have indicated that measurements of   cardiac 
performance and symptoms produced by the disease are 
poorly related. For instance, patients with a very low LVEF 
may be asymptomatic, whereas subjects with just a slightly 
depressed LVEF may have severe disability.35 The apparent 
discordance is not well understood but may be explained in 
part by many noncardiac factors that contribute considerably 
to exercise tolerance such as changes in peripheral vascular 
function, skeletal muscle physiology, pulmonary dynamics, or 
neurohormonal and reflex autonomic activity.36,37 The existence 
of such noncardiac factors may explain why the hemodynamic 
improvement produced by several drugs may not be instantly or 
necessarily translated into improvement in clinical status.
An approach used to quantify the degree of functional 
limitation imposed by HF was first developed by the New 
York Heart Association (NYHA). Severity ranges from 
essentially asymptomatic status – well-treated patients in 
whom symptoms have been relieved (NYHA I) – or slight 
limitation in physical activity (NYHA II), to symptoms while 
walking on the flat (NYHA III) or even breathless at rest 
and essentially housebound (NYHA IV). To get an objective 
evaluation of exercise performance, some form of exercise 
testing is necessary. Corridor walk tests, particularly the   six-
minute walk test, are commonly used due to their low cost and 
simplicity.38 However, to explore exercise limitation in greater 
detail, testing with metabolic gas exchange measurement 
is more useful. Although the functional class tends to 
deteriorate over time, most patients do not typically show an 
inexorable worsening of symptoms. Instead, their severity 
characteristically fluctuates. Medical therapy and diet can have 
either favorable or adverse effects on functional capacity even 
in the absence of significant changes in ventricular   function. 
Some patients may show notable recovery associated with 
improvement in structural and functional abnormalities. When 
such improvement is associated with drug therapy, that therapy 
should be continued indefinitely.
Hospitalizations
As HF progresses, decompensations are more frequent and, 
therefore, hospitalizations increasingly required. Admissions 
with HF may be triggered by a concomitant cardiovascular 
event such as a symptomatic tachyarrhythmia or unstable 
coronary syndrome, medical or dietary noncompliance, or a 
noncardiac condition such as infections or a newly diagnosed 
anemia (Table 5). Unfortunately, the precipitating event 
is not always apparent. HF hospitalizations account for a 
substantial portion of the overall costs of caring and may 
be associated with an astounding worsening in prognosis, 
particularly in the elderly population. In fact, 50% of patients 
are readmitted at six months and 25% to 35% are dead at 
HF
Exercise
Inadequate ↑ stroke
volume
Failure of muscle
perfusion
Stiff/wet lungs
Fatigue Breathlessness
↑ Filling pressure
↓ Functional capacity
Figure 4 Physiopathology of symptoms in heart failure.
Adapted from Clark with permission from BMJ Group Ltd.135
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twelve months.39–43 Indeed, many HF trials now incorporate 
the need for hospital admission as an important endpoint to 
evaluate new therapies.
A decline in hospitalization rates has been observed in 
Western countries during the past decade.44 This may come as 
a surprise in the face of the predicted increase in age-adjusted 
prevalence of HF. However, admissions for HF do not reflect 
the occurrence and prognosis of the disease in the commu-
nity, as they relate only to the more severe stages that need 
in-hospital evaluation and treatment. A fall in hospitalization 
rates may well be due to improved treatment and manage-
ment of patients (eg, development of new drugs and devices, 
HF clinics). In addition, a growing number of patients in the 
terminal stages are being cared for in a home-based setting by 
their general practitioner, rather than admitted to a hospital.
Mortality
The most comprehensive figures on the prognosis of the 
‘average’ HF patients have been obtained in population-
based research, in which incident cases were followed up 
carefully.45–49 Mortality rate is relatively high in the first 
few weeks after the occurrence of HF. However, following 
that period, the survival curve shows a much more gradual 
slope. According to data from different studies conducted in 
America and Europe, 30-day, 1-year, and 5-year mortality 
are around 10% to 20%, 30%, and 65% respectively. The 
mortality rates are higher when only patients hospitalized 
for HF are taken into account.50 In contrast, the risk of death 
in the placebo-treated arm of large randomized trials tends 
to be lower.51 To understand such discrepancies, we have to 
bear in mind that the severity of disease in these patients is 
different from the average patient. HF subjects admitted to 
hospital are often at advanced stages, whereas participants 
in medical trials tend to be healthier.
The vast majority of HF deaths are related to   cardiovascular 
causes. Estimates vary from 50% to 90%, again, depending 
on the population analyzed. Patients with relatively mild 
HF (NYHA functional class I and II) are more susceptible 
to arrhythmias and SCD while those in NYHA functional 
class III and IV often die from end-stage ventricular 
dysfunction.5
Continuous advances in therapy are changing the prog-
nosis in HF, and improving survival. For example, in the 
Framingham heart study, the 1- and 5-year mortality rates 
from HF in men declined from 30% and 70%, respectively, in 
the period 1950 to 1969 to 28% and 59% in the period 1990 
to 1999. In women, 1-year mortality rates decreased from 
28% to 24% and the 5-year mortality rates decreased from 
57% to 45% during the same period.46 These results have 
been confirmed in other population-based studies.52
Prognostic determinants in HF can be arbitrarily catego-
rized in: patient characteristics and comorbidity, laboratory 
measurements, functional parameters and ventricular func-
tion, and interventions received (Table 6).53,54 Importantly, 
these prognostic determinants need not be causally related 
to the prognostic outcome. Age, for example, is an important 
prognostic marker in many diseases even after adjustment 
for other factors. Although age per se may not be causally 
implicated, it is associated with other, often immeasur-
able, conditions that are etiologically involved. Apart from 
age, the NYHA classification has long been recognized as 
an important indicator of survival. The prognosis of HF 
  obviously relates to the cause of HF; patients with HF caused 
by alcohol abuse may recover completely, while the 1-year 
mortality in an acute MI complicated by HF exceeds 50%. 
Comorbidities known to influence survival unfavorably 
include renal dysfunction, depression, and anemia. For the 
reasons outlined above, this does not imply that correction, 
if possible, of these factors improved survival (eg, treatment 
with darbepoetin alpha failed to reduce outcomes in HF 
patients with anemia55).
By using a combination of variables, prognostic scores 
have been developed. One of the most popular is the Seattle 
HF model (validated extensively in five cohorts with a total 
of 9942 HF patients).53 A web-based calculator is available 
at www.seattleheartfailuremodel.org.
economic costs
The economic burden of HF is significant. Approximately 
1% to 2% of total health care expenditure is attributed to 
the diagnosis, treatment, and prevention of HF.56,57 A large 
share of this expenditure is related to the costs of long-term 
Table  5  Common  factors  that  precipitate  hospitalization  for 
heart failure
• Noncompliance with medical regimen, sodium and/or fluid restriction
• Acute myocardial ischemia
• Uncorrected high blood pressure
• Atrial fibrillation and other arrhythmias
•   Recent addition of negative inotropic drugs (eg, verapamil, 
diltiazem, beta blockers)
• Pulmonary embolus
• Nonsteroidal anti-inflammatory drugs
• excessive alcohol or illicit drug use
•   endocrine abnormalities (eg, diabetes mellitus, hyperthyroidism, 
hypothyroidism)
• Concurrent infections (eg, pneumonia, viral illnesses)Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 6 Main prognostic factors in heart failure
Patient characteristics 
and comorbidity
Functional parameters and  
ventricular function indices
Laboratory 
measurements
Interventions 
received
Age NYHA class CT ratio ACeis/ARBs
Gender 6 min walk test BNP/NTproBNP BBs
Aetiology LVeF Hemoglobin Aldosterone antagonists
Diabetes Ventricular mass Creatinine HDZ-nitrates
Renal dysfunction QRS duration iCD
Anemia Sodium levels CRT
Depression LVAD  
Heart transplantation
Adapted from Mosterd and Hoes with permission from BMJ Group Ltd.5
Abbreviations: ACeis, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BNP, brain natriuretic peptide; CRT, cardiac resynchronization 
therapy; CT ratio, cardiothoracic index; HDZ, hydralazide; ICD, implantable cardioverterdefibrillator; LVAD, left ventricle assist device; LVEF, left ventricular ejection 
fraction; NT, N-terminal; NYHA, New York Heart Association. 
complications and productivity losses. In order to manage 
these costs, health care providers increasingly have to focus 
on economically attractive interventions. Pharmacoeconomic 
analyses aid the systematic selection of cost-effective drug 
therapy in an era of increasing cost-containment.
Treatment
The American College of Cardiology (ACC)/American Heart 
Association (AHA) guidelines have identified four stages 
of HF.1 The first two stages are evidently not appropriately 
termed as HF. Stage A consists of patients with conditions 
that are associated with an increased risk for developing HF. 
Subjects with asymptomatic structural and/or functional 
LV disease constitute stage B. Symptomatic and terminal 
HF patients are included in stages C and D, respectively. 
  Importantly, this classification provides a   stepwise approach 
to HF care; in every stage, several interventions are indicated 
in order to improve clinical status and/or prognosis   (Figure 4). 
Each of these will be discussed in detail below.
The goals of treatment are reduction in symptoms, a 
decrease in the rate of hospitalization, and the prevention of 
premature death. The cornerstone of treatment is pharma-
cologic therapy. Lifestyle modification may also be needed. 
Surgery, implantable devices, or even heart transplantation 
may be required in selected cases.
Organization of care
Multidisciplinary intervention focused on educating patients, 
their families, and caregivers about HF, its treatment, in order 
to warrant adherence and optimize its effects,58 and the early 
recognition of and response to clinical worsening (eg, decrease 
in functional capacity or weight gain), with a guidance on 
  flexible dosing of diuretics, has been shown to reduce the 
rate of hospital admissions and mortality.59 The Leonardo 
project, a care management initiative   involving nurses, general 
practitioners, specialists, and patients conducted in a primary 
health care system, demonstrated pronounced effectiveness in 
increasing subjects’ knowledge about their disease, self-care, 
and ability to make changes in health behaviors.60
Remote device monitoring (eg, electrocardiogram, blood 
pressure, body weight) coupled with medical telephone 
  support (telemonitoring) may help to detect early signs of 
cardiac decompensation, allowing optimization of therapy. 
A recent Cochrane review concluded that telemonitoring 
reduced the rate of death from any cause by 44% and the rate 
of HF-related hospitalizations by 21%.61 However, the quality 
of the methods used in the included studies was variable and 
many were small. The Tele-HF (Telemonitoring to Improve 
Heart Failure Outcomes) trial, a large study that   randomized 
1653 patients who had recently been hospitalized for HF 
to undergo either telemonitoring or usual care, found no 
benefits of this strategy.62 The ongoing TIMI-HF (Telemedical 
Interventional Monitoring In Heart Failure) trial will provide 
more data on the effects of this intervention.63
Stages Interventions
A
B
C
D
Management of risk factors
ACEIs/ARBs
BBs
DCI in selected cases
in selected cases
in selected cases
Stage B interventions +
Stage C interventions + 
Diuretics for fluid retention
Aldosterone antagonists
hyidralazine + nitrates
Digoxin
CRT
Palliative care
LVAD
Heart transplantation
Figure  5  American  College  of  Cardiology  (ACC)/American  Heart  Association 
(AHA) stages and therapeutic management of HF.
Abbreviations:  BBs,  beta-blockers;  ACeis,  angiotensin  converting  enzyme 
inhibitors; ARBs, angiotensin receptor blockers; CRT, cardiac resynchronization 
therapy; DCi, Diseases and Conditions index; iCD, implantable cardioverter-
defibrillator; LVAD, left ventricular assist device.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
245
Causes, consequences, and treatment of heart failure
Tests such as standard blood analysis or echocardiograms 
should be scheduled only when needed (eg, to check ion 
levels and renal function in patients on diuretics, to reassess 
EF in cases of clinical deterioration or improvement). Despite 
the efficacy of brain natriuretic peptide (BNP) and N-terminal 
pro–B-type natriuretic peptide (NT-proBNP) measurements 
for the diagnosis of HF,64 their serial determinations to guide 
treatment is controversial.65
End-of-life palliative care should be available for indi-
viduals with end-stage HF.66
Lifestyle and exercise
Restriction of sodium intake is routinely recommended 
although it is based on little evidence.1,2 Several stud-
ies have demonstrated that exercise training improves 
quality of life as well as functional capacity, systolic–
diastolic function and BNP and NT-proBNP expression.67 
  Nevertheless, it remains questionable whether this inter-
vention reduces cardiac deaths and hospitalizations and 
whether disease severity predicts which patients are most 
likely to benefit.68,69
Pharmacological therapy
Although several therapeutic agents have proved to reduce 
morbidity and mortality in patients with HFDEF, no treat-
ment has yet been shown to substantially improve clinical 
outcomes in patients with HFPEF. Therefore, we will focus 
our review on pharmacological therapy for HF patients 
with depressed systolic function.
The pathophysiological aspects of HF are essential for 
understanding drug actions and clinical trial designs. The 
development of HF is characterized by an initial cardiac 
injury that triggers a cascade of neurohormonal responses. 
Either an acute (MI) or a chronic (HBP) insult may alter the 
loading conditions of a normal ventricle, inducing stretch-
ing of myocardial fibers or their loss. This condition evokes 
activation of the RAAS and the sympathetic nervous system. 
In the short term, these actions are beneficial and adaptive, 
maintaining organ perfusion. However, in the long run, this 
abnormal neurohormonal setting leads to myocyte hypertro-
phy, apoptosis, and fibrotic proliferation, resulting in adverse 
remodeling and pump dysfunction. The consequences of 
these structural changes are a reduction in stroke volume, 
an increase in systemic vascular resistance, and the develop-
ment of the signs and symptoms of congestion and hypop-
erfusion. Neurohormonal stimulation, therefore, will be the 
main target of most pharmacological agents for HF. Others, 
such as diuretic or digoxin, will not actuate in the feedback 
mechanisms of the disease but will be helpful in symptomatic 
release (Figure 6).70
Diuretics
Diuretics provide rapid relief for the signs and symptoms 
of congestion. Because no studies have yet demonstrated 
the long-term benefit of these drugs in terms of mortal-
ity, they should be prescribed only to patients who have 
evidence of, or a prior history of, fluid retention. Due to 
their potency, loop diuretics have emerged as the preferred 
agents for use in most subjects; however, thiazide diuretics 
may be preferred in hypertensive HF with mild congestion 
because they present a more persistent effect on BP. The 
timing of administration can be altered for social conve-
nience. Managing diuretic dosage is very important. The 
lowest dose needed to achieve an edema-free state (‘dry 
weight’) should be used (Table 7). Inappropriately low doses 
will result in fluid retention, which can increase the risk 
of treatment with beta-blockers, whereas inappropriately 
high doses will lead to volume contraction, which can lead 
to hypotension and renal insufficiency. Patients with mild 
HF respond favorably to low doses because absorption of 
the drug from the bowel and delivery to the renal tubules 
is fast. However, at advanced stages, bowel edema and 
hypoperfusion may delay absorption and delivery,71 and 
therefore, increasing doses may be required to achieve an 
appropriate effect. In some cases even high doses of diuretic 
are ineffective. The intake of large amounts of dietary 
sodium, treatment with agents that can block their effects, 
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Filling pressure
Stroke volume
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Initial hemodynamic
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Figure  6  Physiopathology  of  heart  failure  and  sites  of  action  of  the  main 
pharmacological agents.
Adapted from Ramani et al.70
Abbreviations: ACeis, angiotensin converting enzyme inhibitors; ADH, antidiuretic 
hormone; ald. ant., aldosterone antagonist; ARBs, angiotensin receptor blockers; BBs, 
beta-blockers; HDZ, hydralazide; HR, heart rate; HTA, heart transplant alone; LV, 
left ventricle; Mi, myocardial infarction; RAAS, renin-angiotensin-aldosterone system; 
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such as nonsteroidal anti-inflammatories,72 or significant 
impairment of renal function or perfusion73 may be the 
cause of such a situation. Generally, diuretic resistance can 
be overcome by parenteral administration (continuous infu-
sion may be more helpful than bolus injection),74 the use 
of two or more diuretics in combination (eg, furosemide 
and metolazone),75 or the addition of drugs that increase 
renal blood flow (eg, positive inotropic agents). Diuretics 
can cause the depletion of important cations (potassium 
and magnesium), which may predispose patients to serious 
cardiac   arrhythmias. Potassium deficits can be corrected by 
the short-term use of potassium supplements. Magnesium 
supplements may also be required. Concomitant administra-
tion of angiotensin-  converting enzyme inhibitors (ACEIs) 
alone or in combination with potassium-retaining agents 
(such as spironolactone) can prevent electrolyte depletion 
in most patients, and thus, when these drugs are prescribed 
long-term, oral potassium supplementation frequently is not 
needed and may be deleterious.
ACeis
ACEIs are the most comprehensively studied agents 
in HF. These drugs not only interfere with the RAAS but also 
enhance the action of kinins and kinin-mediated   prostaglandins, 
which may have beneficial effects in cardiac remodeling as 
seen in animal models.76–78 ACEIs have been evaluated in a 
large number of placebo-controlled trials involving patients 
with a reduced LVEF (,35% to 40%) and a wide range of 
severity of HF (from asymptomatic LV impairment to NYHA 
functional class IV). These studies demonstrated that ACEIs 
improve symptoms, mortality, and the combined risk of death 
or hospitalization.79 Although available data suggests that 
there are no differences among ACEIs in their effects, those 
used in clinical trials are   recommended (Table 6). Treatment 
should be initiated at low doses followed by gradual increments 
attempting to reach target doses of clinical trials or the highest 
tolerated.1,2 The clinical response is generally delayed and may 
require several weeks, months, or longer to become apparent.80 
However, even if symptoms do not improve, long-term treat-
ment with an ACEI should be maintained to reduce the risk of 
death or hospitalization. The most common side effect of these 
agents is related to the suppression of angiotensin stimulation 
(hypotension and worsening of renal function) and to kinin 
enhancement (angioedema and cough).
•	 Symptomatic hypotension (eg, dizziness) often improves 
with time although the dose of diuretics and other 
hypotensive agents may need to be reduced.
•	 An increase in serum creatinine is expected after the initia-
tion of an ACEI but is not considered clinically important 
unless rapid and substantial. Renal function is usually 
restored after a reduction in the dose of concomitantly 
administered diuretics, so these patients can generally be 
managed without withdrawing treatment with ACEIs.81
•	 Hyperkaliemia is generally seen in patients whose renal 
function deteriorates or who are taking oral potassium 
supplements or potassium-sparing diuretics.
•	 Cough is the most common reason for the withdrawal 
of long-term treatment with ACEIs.82 Its frequency is 
approximately 5% to 10% in white patients of European 
descent and rises to nearly 50% in Chinese patients.83
•	 Angioedema occurs in ,1% of patents taking an ACEI 
but is more frequent in black patients. Because its occur-
rence may be life-threatening, the clinical suspicion of 
this reaction justifies subsequent avoidance of all ACEIs 
for the lifetime of the patient.82
Table 7 Diuretics, beta-blockers, angiotensin converting enzyme 
inhibitors,  angiotensin  receptor  blockers,  and  aldosterone 
antagonists recommended in heart failure
Loop diureticsa Initial dose (mg) Usual daily dose (mg)
Furosemide 20–40 40–240
Bumetanide 0.5–1.0 1–5
Torasemide 5–10 10–20
Thiazidesb Initial dose (mg) Usual daily dose (mg)
Bendroflumethiazide 2.5 2.5–10
Hydrochlorothiazide 25 12.5–100
Metolazone 2.5 2.5–10
lndapamidec 2.5 2.5–5
ACEIs Initial dose (mg) Target dose (mg)
Captopril 6.25 ttd 50–100 ttd
enalapril 2.5 td 10–20 td
iisinopril 2.5–5.0 od 20–35 od
Ramipril 2.5 od 5 td
Trandolapril 0.5 od 4 od
ARBs Initial dose (mg) Target dose (mg)
Candesartan 4 to 8 od 32 od
Valsartan 20 to 40 td 160 td
Losartan 25 to 50 od 50 to 100 od
BBs Initial dose (mg) Target dose (mg)
Carvedilol 3.125 td 25 td
Bisoprolol 1.25 od 10 od
Metoprolol 12.5 od 200 od
Nevibolol 1.25 od 10 od
Ald. ant. Initial dose (mg) Target dose (mg)
Spironolactone 25 od 25–50 od
eplerenone 25 od 50 od
Notes: aDose  might  need  to  be  adjusted  according  to  volume  status/weight; 
excessive dose may cause renal impairment and ototoxicity; bDo not use thiazides 
if eGFR. 30 mL/min, except when prescribed synergistically with loop duretics; 
cindapamide is non-thiazide sulfonamide.
Abbreviations:  BBs,  beta-blockers;  ACeis,  angiotensin-converting  enzyme 
inhibitors; Ald. ant., aldosterone antagonists; ARBs, angiotensin receptor blockers; 
eGFR, estimated glomerular filtration rate; od, once daily; td, twice daily; ttd, three 
times daily.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Angiotensin receptor blockers
Circulating levels of angiotensin II increase to pretreatment 
levels with long-term ACEI inhibition.84 Angiotensin   receptor 
blockers (ARBs) bind competitively to the AT1 receptor, 
providing a downstream effect and thereby   dampening this 
escape phenomenon.85 Besides, interference with the RAAS 
without inhibition of kininase would provide the benefits of 
ACEIs while minimizing their adverse reactions.86   However, 
as mentioned before, it is now known that some of the 
  benefits of ACEIs may be related to the accumulation of 
kinins, whereas some of the their side effects are related to 
the suppression of angiotensin II formation. A large meta-
analysis of 24 randomized trials showed the superiority of 
ARBs to placebo in patients with intolerance to ACEIs and 
their noninferiority in all-cause mortality or hospitalizations 
when compared directly with ACEIs.87 Taking into account 
this evidence, ARBs are used as an alternative to ACEIs when 
cough or angioedema is developed. Because combination 
therapy of ACEIs and ARBs results in a modest decrease 
in hospitalization (relative risk reduction [RRR]: 17%), an 
increase in side effects, and no benefits on mortality,88 its 
use is controversial.1,2 ARBs recommended in guidelines 
are listed in Table 7.
Beta blockers
The benefits of three beta-blockers (BBs), bisoprolol, 
metoprolol succinate (β1 receptor selective blockers), and 
carvedilol (which blocks α1, β1, and β2 receptors), have 
been assessed in several placebo-controlled trials enroll-
ing patients with a reduced LVEF (,35% to 45%), mostly 
under ACEIs therapy, from initial to advance stages of 
HF. 89–93 Long-term treatment with BBs has been shown to 
lessen symptoms, reduce mortality and the combined risk 
of death and hospital admission. In the SENIORS (Study 
of the Effects of Nebivolol Intervention on Outcomes 
and Rehospitalization in Seniors with heart failure) trial, 
nebivolol, another β1 receptor blocker, demonstrated efficacy 
in reducing the combined endpoint of death or cardiovascular 
hospitalization in elderly patients (.70 years) with HF.94 
Although no randomized controlled trials of BBs in individu-
als with asymptomatic LV dysfunction have been completed, 
their use (especially in those with CAD) is encouraged.2 
Bearing in mind that most participants in BB trials were 
not on target doses on ACEIs and the fact that adding a BB 
produces a greater improvement in clinical status and mor-
tality than increasing ACEIs,95,96 patients do not need to be 
on high doses of ACEIs before initiating therapy with BBs. 
Dose titration and time to clinical response considerations 
for ACEIs also apply to BBs (Table 7). Because long-term 
treatment with BBs reduces the risk of worsening HF, dis-
continuation of these drugs after an episode of decompensa-
tion is not recommended.1,2 However, in unstable subjects 
it may be prudent to reduce its dose temporarily until the 
basal status is recovered.
The most common side effects of BBs include:
•	 Fatigue or weakness. In many cases it resolves sponta-
neously within several weeks; however, in some cases, 
it may be severe enough to limit dose increase or even 
necessitate treatment withdrawal.
•	 Bradycardia. The slowing of heart rate (HR) is   generally 
well tolerated. Nevertheless, when symptoms or an 
advanced heart block is developed BB dose should be 
reduced.
•	 Symptomatic hypotension may be managed by adminis-
tering BBs and ACEIs at different times during the day. 
If this is ineffective, a temporary reduction in the dose of 
diuretics (in patients who are volume depleted) or ACEIs 
may be effective.
Aldosterone antagonists
Although short-term therapy with both ACEIs and ARBs 
can lower circulating levels of aldosterone, such suppres-
sion may not be sustained during long-term treatment.97 
This observation may be important because aldosterone 
promotes sodium retention, electrolyte imbalances, and 
endothelial dysfunction and may directly contribute 
to myocardial fibrosis.98 In the RALES (Randomized 
Spironolactone Evaluation Study) trial, a low dose 
of spironolactone, the most widely used aldosterone 
antagonist, added to ACE therapy in NYHA class III and 
IV patients, reduced mortality and HF hospitalizations. 
Functional class also improved.99 The EPHESUS (Epler-
enone Post-Acute Myocardial Infarction Heart Failure 
Efficacy and Survival Study) trial investigated the newer 
aldosterone antagonist eplerenone in subjects with LVEF 
# 40% and clinical evidence of HF or diabetes mellitus 
within 14 days after MI, and found a decrease in the risk 
of death.100 The recently published EMPHASIS-trial, 
whose participants had an LVEF # 35% and were in 
NYHA functional class II, showed that eplerenone sig-
nificantly reduced mortality and hospital admissions.101 
This promising result may extend the actual indication for 
aldosterone antagonists (NYHA functional class III–IV) 
in HF to early stages of the disease. The main side effects 
related to aldosterone antagonists are hyperkalemia and 
gynecomastia.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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•	 Hyperkalemia is a concern, especially in subjects with 
underlying chronic kidney disease, so serum potassium 
levels must be closely monitored.
•	 Gynecomastia can occur during therapy with spironolac-
tone but not in patients treated with eplerenone, and thus, 
switching from one agent to the other one may solve the 
problem.
The dosage of aldosterone antagonists is listed in Table 7.
Hydralazine and nitrates
Hydralazine produces arterial vasodilation and systemic 
vascular resistance reduction via modulation of intracellular 
calcium kinetics, and nitrates are transformed in smooth 
muscle cells into nitric oxide, which stimulates cyclic 
guanosine monophosphate production and subsequent   arterial 
vasodilation. This combination increases survival in HF, but 
not as much as with ACEIs or ARBs.102,103 The A-Heft trial, 
conducted in African Americans with advanced HF who were 
receiving standard therapy (including BBs and ACEIs), found 
that the addition of a fixed-dose isosorbidedinitrate and hydral-
azine enhanced survival and decreased   hospitalizations.104 
According to these data, combination therapy with hydralazine 
and nitrates may be an option for patients in which ACEIs or 
ARBs are contraindicated and also in African American HF 
subjects who remain symptomatic (NYHA functional class 
III–IV) despite optimal medical therapy.1,2
Digoxine
In addition to their mild inotropic effect, digitalis glycosides 
attenuate carotid sinus baroreceptors and have sympathoin-
hibitory effects that produce a decrease in norepinephrine, 
renin, and possibly aldosterone levels.105,106 In the only 
randomized-controlled trial of digoxin therapy (DIG trial) a 
reduction in hospitalizations (RRR 28%) among individuals 
with HF and LVEF , 45% was found, although no overall 
mortality benefit was achieved.107 In daily practice, digoxin is 
used in addition to BBs to control HR in patients with atrial 
fibrillation as well as in those with persisting symptoms even 
with optimal medical treatment.1,2 Dosage should be adjusted 
to obtain serum levels between 0.6 and 1.2 ng/mL. Common 
side effects include bradyarrhythmias and tachyarrhythmias 
(digoxin-specific Fab antibody fragments may be required 
in some cases), gastrointestinal symptoms (eg, anorexia, 
nausea, and vomiting), and neurological complaints (eg, 
visual disturbances, disorientation, and confusion). Although 
digitalis toxicity is commonly associated with high serum 
digoxin levels (.2 ng/mL) it may occur with lower levels, 
especially if hypokalemia coexists.
Surgery
Coronary revascularization
A meta-analysis of 24 studies investigating late survival 
in patients with ischemic HF treated with coronary artery 
bypass grafting (CABG) or medical therapy showed a RRR 
of 79% in annual mortality in those with myocardial viability. 
  Nevertheless, no incremental benefit with CABG was found in 
individuals without substantial viability.108   Revascularization 
is strongly supported in patients with angina, whereas 
there is no evidence to sustain it in   individuals with multives-
sel CAD but no ischemic symptoms. An ongoing randomized 
trial will clarify this matter.109
Mitral valve repair
Functional MR, characterized by annular dilatation and 
leaflet non-coaptation in the setting of anatomically normal 
papillary muscles, chordal structures, and valve leaflets, is 
frequent in patients with HF. Although severe functional MR 
is associated with poor prognosis, it has been demonstrated 
that valve repair improves only symptoms but does not reduce 
mortality. Besides, recurrence in the first year may reach up 
to 35% of cases. Therefore the indication for this surgical 
technique is controversial and must be individualized.110
Ischemic MR found in patients with previous MI is 
typically associated with leaflet tethering and displacement 
related to abnormal LV wall motion and geometry. Despite 
current guidelines recommending mitral valve repair in 
patients with moderate and severe ischemic MR who are 
considered for CABG surgery, long-term benefits are still 
unclear.111
Ventricular reconstruction
Multiple surgical techniques to reduce LV volume and 
thereby alleviate wall stress have been utilized. The 
recently published STICH (Surgical Treatment of Ischemic 
Heart Failure) trial randomized patients with ischemic LV 
dysfunction undergoing CABG to isolated CABG versus 
CABG plus surgical ventricular reconstruction. Although 
surgical reconstruction reduced LV volumes, no difference in 
mortality or hospital admissions was found.112 On the basis of 
these results, routine surgical LV reconstruction in addition 
to CABG is not recommended.
Devices
Implantable cardioverter-defibrillator
Implantable cardioverter-defibrillator (ICD) reduces the 
risk of SCD due to severe ventricular arrhythmias. Patients 
at higher risk are those with a previous MI and a severely Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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reduced LVEF. The MADIT II (Multicentric Automatic 
Defibrillator Implantation II) trial, whose participants had a 
nonrecent MI and LVEF , 30%, found a significant survival 
benefit after ICD implantation.113 Similar results were showed 
SCD-HeFT (Sudden Cardiac Death in Heart Failure) trial 
which evaluated patients with nonischemic or ischemic LV 
systolic dysfunction (LVEF < 35%).114 According to current 
guidelines, ICD is indicated for secondary prevention in 
patients who survive an unprovoked episode of ventricular 
fibrillation or   sustained ventricular tachycardia and for pri-
mary prevention in patients with LV dysfunction (LVEF # 
35%). In ischemic LV dysfunction, evaluation of LVEF and 
subsequent device implantation should be done three months 
after an elective revascularization and 40 days after a prior 
MI. NYHA functional class II or III, optimal medical therapy, 
and expected survival with good functional status for .1 year 
are required to implant an ICD in nonischemic LV systolic 
dysfunction. In cases of ischemic LV dysfunction this indica-
tion is extended to NYHA functional class I.115
Cardiac-resynchronization therapy (CRT)
Intraventricular conduction delays, identified by a QRS 
interval of .120 ms, occur in up to one-third of patients with 
severe systolic HF, and are associated with dyssynchronous 
contraction of the LV, which leads to impaired emptying 
and, in some patients, MR.116 Early studies showed that CRT 
has a positive effect on reverse remodeling (manifested by a 
decrease in LV volumes and an increase in LVEF), improves 
exercise capacity, and reduces symptoms.117 The CARE-HF 
(Cardiac Resynchronization in Heart Failure) trial was the first 
study to demonstrate a benefit in all-cause mortality with this 
treatment.118 A meta-analysis of 14 randomized trials of CRT 
confirmed a significant lessening in morbidity and mortality.119 
In contrast, this therapy has not been successful in HF patients 
with narrow QRS.120 Although many echocardiographic 
parameters of dyssynchronous have been proposed to identify 
candidates for CRT, no one has shown efficacy for predicting 
responders,121 and therefore, to date, they are not routinely 
used in daily practice. The recently published MADIT-CRT 
trial, which involved patients with NYHA functional class I or 
II, LVEF of 30% or less, and wide QRS intervals ($130 ms), 
found that CRT added to an ICD improved ventricular function 
and reduced the risk of worsening HF in comparison with 
ICD alone. These effects were most marked in subjects with 
a QRS interval of $150 ms.122 Participants in the REVERSE 
(Resynchronization Reverses Remodeling in Systolic Left 
Ventricular Dysfunction) trial (NYHA function class I or II, 
LVEF # 40%, QRS duration $120 ms, and LV end-diastolic 
diameter $55 mm) were randomly assigned to CRT activated 
versus CRT off. After 12 months, a positive effect on reverse 
remodeling was achieved in the CRT-activated group, but no 
difference in clinical outcomes was found.123 The European 
sample of REVERSE comprised 262 patients, followed up to 
24 months. In this population, fewer patients assigned to CRT 
worsened clinically.124 Similarly, the time to first hospitalization 
for HF or to death from any cause was significantly delayed. 
The results from these two trials have recently changed the 
European Society of Cardiology recommendations for CRT 
(Table 8).125 The advantage of CRT plus ICD (CRT-D) over 
CRT alone in terms of survival has not been adequately 
addressed. However, because of the documented effectiveness 
of ICD therapy for prevention of SCD, the use of a CRT-D 
device is commonly preferred.
Left ventricular assist devices
Given the shortage of organ donors there has been a grow-
ing interest in left ventricular assist devices (LVAD) as a 
bridge to transplantation or even as a definitive therapy for 
end-stage HF individuals. The REMATCH trial, conducted 
in patients with terminal HF ineligible for heart trans-
plantation, showed that LVAD increased 1-year survival 
rates as compared with medical treatment (52% vs 25% 
respectively).126 Technological advances have led to the devel-
opment of more effective and safer devices. In a recent study 
Table  8  Actual  european  recommendations  for  cardiac 
resynchronization therapy
Sinus rhythm
NYHA function class iii/iV
	•  LVeF # 35%
	•  QRS $ 120 ms
	•  Optimal medical therapy
	•  Class iV patients should be ambulatorya
NYHA function class ii
	•  LVeF # 35%
	•  QRS $ 150 ms
	•  Optimal medical therapy
Atrial fibrillation
NYHA function class lll/iV
	•  LVeF # 35%
	•  QRS $ 130 ms
	•  Optimal medical therapy
	•    Pacemaker dependency induced by AV nodal ablation or slow 
ventricular rate and frequent pacingb
Pacemaker indication
	•  LVeF # 35%c
Notes: aNo admissions for HF during the last month and a reasonable expectation 
of survival .6 months; bFrequent pacing is defined as $95% pacemaker dependence; 
cindication iiaC in NYHA iii-iV and iibC in NYHA ii.
Abbreviations:  AV,  atrioventricular;  HF,  heart  failure;  LVeF,  left  ventricular 
ejection fraction; NYHA, New York Heart Association.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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comparing new continuous flow LVAD with old pulsatile 
volume-displacement LVAD in subjects with end-stage HF, 
the 2-year survival was significantly higher with the new 
device than with the older (46% vs 11%).127 Despite these 
promising results, current devices are expensive and may 
cause serious complications such as infection, bleeding, and 
malfunction. Therefore,   candidates for this therapy must be 
carefully selected.
Heart transplantation
Heart transplantation is a last resort for patients with 
  refractory HF. The development of immunosuppressive 
agents has dramatically reduced the rate of graft rejection 
and led to good survival rates (the estimated half-life heart 
transplantation exceeds 10 years) with a good quality of 
life.128 However, serious comorbidities must be ruled out and 
an ability to adhere to the intensive postoperative medical 
treatment and follow-up required should be confirmed before 
offering a patient this therapeutic option.
Novel therapies
Ivabradine acts on the If  ion current, which is highly 
expressed in the sinoatrial node. If is a mixed Na+–K+ inward 
current activated by hyperpolarization and modulated by the 
autonomic nervous system. It is one of the most important 
ionic currents for regulating pacemaker activity in the sino-
atrial node. Ivabradine selectively inhibits this current in a 
dose-dependent manner, slowing the HR. The drug has few 
other, if any, known cardiac effects. The SHIFT (Systolic 
Heart Failure Treatment with the IF Inhibitor Ivabradine) 
trial investigated the effects of ivabradine in HF patients 
with reduced LVEF (#35%) and HR . 70 beats per minute, 
showing a reduction in the rate of cardiovascular death and 
cardiovascular hospital admissions.129 These results confirm 
the importance of HR in HF and support the concept that its 
decrease contributes significantly to reduce outcomes.
Treatment of HFPeF
Identification of specific therapeutic agents has been disap-
pointing. Effective drugs in HFDEF such as ACEIs, ARBs, 
BBs, and digoxin showed no benefits in HFPED.130–133 
  Therefore, guidelines focus on appropriate treatment of the 
underlying cause (basically BP and ischemia), rate/rhythm 
control if AF is developed, and control of   pulmonary con-
gestion with diuretic agents.1,2   Venodilators such as nitrates 
should be used with caution because decreases in preload 
may lead to an excessive reduction in LV filling, resulting in 
hypotension and syncope.
Treatment of isolated right HF
The most important aspect of managing right HF is tailoring 
therapy to its specific cause. In contrast to patients with 
chronic left HF, patients with right HF often have signifi-
cantly abnormal afterload (eg, pulmonary hypertension) or 
valvular heart disease (eg, acquired or congenital pulmonary 
or tricuspid disease). It is therefore not surprising that the 
selected treatment should primarily target the etiology of the 
disease. Sodium and fluid restriction and judicious use of 
diuretics all help to optimize preload which, in the major-
ity of patients, is achieved at normal right atrial pressure 
(,6 mmHg). Only small studies suggest a beneficial role 
for beta   blockade or ACE inhibitors. Primary prevention of 
sudden death using defibrillators is recommended mainly in 
patients with ARVC and tetralogy of Fallot. In the setting of 
acute right HF, every effort should be made to avoid systemic 
  hypotension, as this could lead to myocardial ischemia and 
further hypotension.134
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